BPaL Treatment: A Ray of Hope for MDR-TB Patients

Authors

  • Zafar Iqbal Department of Pulmonology, Lady Reading Hospital, Peshawar - Pakistan
  • Uzma Hidayat Programmatic Management of Drug Resistant TB Unit, Lady Reading Hospital, Peshawar – Pakistan

DOI:

https://doi.org/10.1996/pjcm.v28i3.894

Keywords:

Drug Resistant TB, MDR-TB, BPal Treatment

Abstract

  BPaL treatment, comprising bedaquiline, pretomanid, and linezolid, offers a promising ray of hope for patients suffering from multidrug-resistant tuberculosis (MDR-TB). This novel combination therapy has demonstrated remarkable efficacy in treating MDR-TB cases, particularly those with limited treatment options due to resistance or intolerance to conventional medications. Through rigorous clinical trials, BPaL has shown significantly higher success rates in achieving culture conversion and favorable outcomes compared to previous regimens, marking a significant advancement in the fight against MDR-TB. With its potential to reduce treatment duration and improve patient outcomes, BPaL represents a critical breakthrough in tuberculosis management, offering new hope for patients grappling with this challenging infectious disease. Keywords: Drug Resistant TB; MDR-TB; BPal Treatment

References

Khan MA, Mehreen S, Basit A, Khan RA, Jan F, Ullah I, et al. Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan. Saudi Med J. 2015;36(12):1463.

Iqbal Z, Batool R, Khan MA, Ali SZ, Asif M. Predictors of Unsuccessful Interim Treatment Outcomes and Culture Conversion among Multidrug-Resistant Tuberculosis Patients in Pakistan. IJONS.2021; 64(11): 29253-64

Javaid A, Khan MA, Jan F, Rauf M, Khan MA, Basit A, Mehreen S. Occurrence of adverse events in a patient receiving community-based therapy for multidrug-resistant tuberculosis in Pakistan. Tuberkulozvetoraks. 2018;66(1):16-25.

Khan MA, Aziz A, Ullah U, Ullah N, Jan F, Nasir SM, Javaid A. Treatment Outcomes of Short Course Regimens for Multidrug-Resistant Tuberculosis Patients in Peshawar. Pak J Chest Med. 2020;26(4):210-6.

Gupta A, Juneja S, Sahu S, Yassin M, Brigden G, Wandwalo E, Rane S, Mirzayev F, Zignol M. Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis. PLOS Glob Pub Health. 2022;2(11):e0001287.

Mahardani PN, Wati DK, Siloam A, Savitri NP, Manggala AK. Effectiveness and safety of short-term regimen for multidrug-resistant tuberculosis treatment: a systematic review of cohort studies. Oman Med J. 2022;37(1):e337.

Prasad R, Saxena H, Gupta N, Tanzeem M, Naorem R. Treatment of Drug-Resistant Tuberculosis: Current Status. Ann National Acad Med Sci. 2020;57(02):068-73.

Putra ON, Faizah AK, DN NW. Six Months of Bedaquiline-Pretomanid-Linezolid (BPaL) Regimen in Patients with Drug-Resistant Tuberculosis: A Narrative Review. Journal of Endocrinology, Trop Med Infect Dis. 2023;5(2):83-95.

Downloads

Published

2022-09-02

How to Cite

Iqbal, Z., & Hidayat, U. (2022). BPaL Treatment: A Ray of Hope for MDR-TB Patients. Pakistan Journal of Chest Medicine, 28(3), 279–281. https://doi.org/10.1996/pjcm.v28i3.894

Issue

Vol. 28 No. 3 (2022)

Section

Editorial

License

Copyright (c) 2022 Pakistan Journal of Chest Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>